Home » Newsletters » BioWorld Science

BioWorld Science

June 27, 2012

View Archived Issues

Allergan divulges new S1P1 receptor ligands

Scientists at Exelixis design novel inhibitors of protein kinases

Mavoglurant studies reported at various conferences

CC-223 well tolerated in early-stage clinical study

Promising first-in-human results disclosed for CH-5132799

New Acceleron Pharma drug reduces anemia in model of myelodysplastic syndromes

New levodopa prodrugs presented by Ono Pharmaceutical

New acetyl-CoA carboxylase inhibitors prepared in Japan

Bispecific tetravalent cancer immunotherapic is efficacious and safe in vivo

Sirnaomics awarded NIH grant for siRNA therapeutic

PPI-668 shows promise in patients with HCV infection

Nissan Chemical Industry reports novel anticancer agents

Researchers at Esteve synthesize new agents for pain

Dosing begins in RXI-109 dermal scarring study

Roche decides against exercising opt-in rights to Biotie drug

FDA sets PDUFA date for Heplisav BLA

CHMP issues opinion on subcutaneous use of Velcade

Preclinical development of leishmaniasis vaccine complete

Medivir and Swedish University of Agricultural Sciences launch collaboration

Cellceutix set to kick off phase I trial of Kevetrin

Fuji Film Pharma acquires Japanese marketing rights for three products from Bayer Yakuhin

Astellas Pharma submits MAA for enzalutamide

NICE recommends new treatment options for prostate and lung cancer

Novel S1P4 receptor ligands disclosed

BioSpecifics Technologies commences phase II Xiaflex trial

New NanoTherm research agreement initiated

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...